Jinweike Biotechnology

Chengdu Jinweike Biotechnology Co., Ltd. (Jinweike Biotechnology, Genevector) is a biotechnology company engaged in the research and development of new drugs for adeno-associated virus (AAV) gene therapy. The company is committed to the development of new AAV gene therapies for ophthalmic diseases, neuromuscular diseases, and inherited metabolic diseases. The core management team of Jinweike Biotechnology comes from well-known pharmaceutical companies, research institutions, and universities in China, including scientists who are deeply engaged in research fields as well as elites from the industry and business sectors. The core technical team's expertise covers upstream technology for product development, pilot-scale process research, quality research, and GMP production, with integrated R&D capabilities ranging from product design and development, process and formulation development, to quality standard research.